The IHC panel has expanded to include markers used in the work-up of LPDs (BCL2, BCL6, CD10, CD30, CD138, MPO, MUM1 PAX5, and TdT), breast cancer (HER2), tumor differentiation (AE1/AE3, S100, synaptophysin, and neurofilament), and, with the support of Baylor College of Medicine Children’s Foundation-Malawi, pediatric small round blue cell tumors (CD99, desmin, and myogenin). This evidence concerns the gene SDC1 and breast carcinoma.